glp-1 receptor agonist and dpp-4 inhibitor combination not recommended inhibitors for type 2 diabetes management Frontiers | The risk of

doi: 10.1023/A:1018863716749 160 SchirraJHouckPWankUArnoldRGkeBKatschinskiM

GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD

Guidelines for treating Type 2 diabetes, like the same American Diabetes Associations (ADAs), generally recommend that patients receive metformin, and if necessary, the addition of other medication(s) like: A dipeptidyl peptidase-4 (DPP-4) inhibitor like Januvia, A Glucagon-like peptide-1 (GLP-1) receptor agonists receptor agonist like Ozempic, A sodium glucose co-transporter 2 (SGLT-2) inhibitor like Invokana, and / or A thiazolidinediones (TZD) like pioglitazone

Unlike past medications for losing weight, which relied on powerful stimulants with dangerous side effects, GLP-1 agonists seem to have been the first drugs that provided effective long-term weight loss without any risk of harm

It is important to consider the timing of a switch between treatments

29,37 The biological basis of these differences remains poorly understood, and current evidence is largely derived from adult populations